ArticleZoological research2025
Peptide OM-LV20 demonstrates neuroprotective effects by attenuating mitochondria-mediated neuronal apoptosis and dysfunction in mice with traumatic brain injury.
Article in Zoological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From marine predator to pharmacology: Conotoxin diversity, discovery, and therapeutic potential.Zoological research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) remains a major public health challenge worldwide, particularly among individuals under 45 years of age, resulting in profound physical disability, neuropsychiatric impairment, and socioeconomic burden. Existing therapeutic strategies offer limited efficacy, underscoring the urgent need for novel treatment modalities. This study evaluated the neuroprotective potential of OM-LV20, an amphibian-derived bioactive peptide, in a murine model of TBI. Intraperitoneal administration of OM-LV20 following controlled cortical impact significantly reduced brain water content and attenuated neurological and cognitive deficits. Histological analysis, TUNEL staining, and ultrastructural assessments revealed suppression of neuronal degeneration and mitigation of mitochondrial dysfunction. Transcriptomic profiling, together with RT-qPCR and western blot analyses, revealed modulation of the expression of apoptosis-related genes and proteins, indicating a robust anti-apoptotic effect mediated through mitochondrial pathways. Additionally, OM-LV20 exhibited efficient permeability across the blood-brain barrier. These findings indicate that OM-LV20 exerted strong neuroprotective activity through targeted suppression of mitochondria-centered neuronal apoptosis, supporting its potential utility in ameliorating neurological dysfunction post-TBI. The diverse mechanistic actions identified for OM-LV20 provide a novel therapeutic avenue with considerable promise for enhancing neurological recovery in individuals with TBI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.